Second-generation antipsychotics and the metabolic syndrome

Current Psychiatry Reports

Volumn 7, Issue 3, 2005, Pages 153-154

  Masand, Prakash S ^a   Mago, Rajnish ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

BODY WEIGHT DISORDER; CLINICAL PRACTICE; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; HEALTH SURVEY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID ANALYSIS; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; NOTE; OBESITY; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PSYCHIATRIST; PSYCHOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TARDIVE DYSKINESIA;

EID: 21444444553     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-005-0044-1     Document Type: Note

References (6)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
2. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414-425.
3. Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
4. Wirshing DA, Pierre JM, Erhart SM, Boyd JA: Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin N Am 2003, 26:165-190.
5. Newcomer JW, Nasrallah HA, Loebel AD: The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004, 24(Suppl 1):S1-6.
6. Nasrallah HA, Newcomer TW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004, 24(Suppl 1):S7-14.